Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross David M.; Masszi Tamas; Gomez Casares Maria Teresa; Hellmann Andrzej; Stentoft Jesper; Conneally Eibhlin; Garcia-Gutierrez Valentin; Gattermann Norbert; le Coutre Philipp D.; Martino Bruno; Saussele Susanne; Giles Francis J.; Radich Jerald P.; Saglio Giuseppe; Deng Weiping; Krunic Nancy; Bedoucha Veronique; Gopalakrishna Prashanth; Hochhaus Andreas

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

【24h】

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

机译：慢性骨髓白血病患者在慢性期慢性期核心核尼洛尼布患者的无耐药性缓解：96周的Enestfreedom研究更新

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.

机译：目的Enestfreedom正在评估慢性骨髓白血病（CML）慢性阶段的慢性骨髓性白血病患者后的无治疗缓解（TFR）。在48周的主要分析之后，我们在这里提供更新的96周分析。

著录项

来源
《Journal of Cancer Research and Clinical Oncology》 |2018年第5期|共10页
作者
Ross David M.; Masszi Tamas; Gomez Casares Maria Teresa; Hellmann Andrzej; Stentoft Jesper; Conneally Eibhlin; Garcia-Gutierrez Valentin; Gattermann Norbert; le Coutre Philipp D.; Martino Bruno; Saussele Susanne; Giles Francis J.; Radich Jerald P.; Saglio Giuseppe; Deng Weiping; Krunic Nancy; Bedoucha Veronique; Gopalakrishna Prashanth; Hochhaus Andreas;
展开▼
作者单位

SA Pathol Royal Adelaide Hosp Div Haematol Room 6E359 1 Port Rd Adelaide SA 5000 Australia;

Semmelweis Univ Budapest Hungary;

Hosp Univ Gran Canaria Dr Negrin Las Palmas Gran Canaria Spain;

Med Univ Gdansk Gdansk Poland;

Aarhus Univ Hosp Aarhus Denmark;

St James Hosp Dublin Ireland;

Hosp Univ Ramon y Cajal IRYCIS Madrid Spain;

Univ Klinikum Dusseldorf Dusseldorf Germany;

Charite Univ Med Berlin Berlin Germany;

Azienda Osped Bianchi Melacrino Morelli Reggio Di Calabria Italy;

Heidelberg Univ Med Fak Mannheim Med Klin 3 Mannheim Germany;

Dev Therapeut Consortium Chicago IL USA;

Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;

Univ Turin Orbassano Italy;

Novartis Pharmaceut E Hanover NJ USA;

Novartis Inst BioMed Res Cambridge MA USA;

Novartis Pharma AG Basel Switzerland;

Novartis Pharma AG Basel Switzerland;

Univ Klinikum Jena Abt Hamatol Onkol Jena Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Chronic myeloid leukemia; Treatment-free remission; Predictors of TFR; Nilotinib; Frontline; Clinical trial;

机译：慢性骨髓白血病;无治疗缓解;TFR的预测因子;NILOTINIB;前线;临床试验;

相似文献

外文文献
中文文献
专利

1. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study [J] . Ross David M., Masszi Tamas, Gomez Casares Maria Teresa, Journal of Cancer Research and Clinical Oncology . 2018,第5期

机译：慢性骨髓白血病患者在慢性期慢性期核心核尼洛尼布患者的无耐药性缓解：96周的Enestfreedom研究更新
2. Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study [J] . Radich Jerald P., Ross David M., Masszi Tamas, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：在慢性期慢性骨髓白血病患者的前线NILOTINIB（CML-CP）中的无治疗缓解（TFR）：来自Enestfreedom研究的192周数
3. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study [J] . AHochhaus, TMasszi, F JGiles, Leukemia . 2017,第7期

机译：慢性期慢性粒细胞白血病患者一线尼罗替尼治疗后的无治疗缓解：ENESTfreedom研究的结果
4. Plasma metabolite profiling of chronic myeloid leukemia patients [C] . Radana Karlikova, Marcela Hrda, Jitka Siroka, International Mass Spectrometry Conference . 2014

机译：慢性骨髓白血病患者的血浆代谢物分析
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study [O] . David M. Ross, Tamas Masszi, María Teresa Gómez Casares, -1

机译：一线尼罗替尼治疗后慢性期慢性粒细胞白血病患者的持久无治疗缓解：ENESTfreedom研究的96周更新
7. Faculty Opinions recommendation of Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. [O] . Daniela Krause 2021

机译：教师意见建议慢性骨髓白血病患者慢性骨髓性白血病患者的推荐慢性期：96周的Enestfreedom研究更新。

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

摘要

著录项

相似文献

相关主题

期刊订阅